As an emerging therapeutic target for metabolic diseases and age-related metabolic decline, ERRα holds promise for treating conditions such as obesity, muscle wasting, and CVDs, by improving mitochondrial function and oxidative metabolism. The gene discussed is ESRRA; the disease is obesity due to melanocortin 4 receptor deficiency.